AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19330596 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-picture test
Number of subjects: 112
Study 19330596 — intervention group
Group type: EXPERIMENTAL
Intervention: Free recall
Number of subjects: 112
Study 19330596 — intervention group
Group type: EXPERIMENTAL
Intervention: Long delay reproduction (24 hours)
Number of subjects: 112
Study 19330596 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory test with free recall of words after a long delay
Number of subjects: 112
Study 16926835 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paclitaxel (SMEOF#3) 160 mg + CsA 700 mg
Number of subjects: 7
Study 16926835 — intervention group
Group type: COMPARATOR
Intervention: Oral paclitaxel (Taxol) 160 mg + CsA 700 mg
Number of subjects: 7
Study 16926835 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paclitaxel (Taxol) 160 mg
Number of subjects: 7
Study 15228716 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg/child)
Number of subjects: 20
Study 15228716 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg/child) + Praziquantel (20 mg/kg)
Number of subjects: 20
Study 11782039 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal pilot study design
Number of subjects: 0
Study 11782039 — intervention group
Group type: COMPARATOR
Intervention: Blinded sample size recalculation procedures
Number of subjects: 0
Study 11782039 — intervention group
Group type: EXPERIMENTAL
Intervention: Study designs allowing for early stopping
Number of subjects: 0
Study 8517903 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 105
Study 8517903 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 105
Study 3203713 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal release methyldopa
Number of subjects: 10
Study 3203713 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release methyldopa
Number of subjects: 10
Study 3203713 — intervention group
Group type: COMPARATOR
Intervention: Both formulations of methyldopa
Number of subjects: 10
Study 30659416 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined upper limb and breathing exercise (2 days/week, 60 min/session) with independent home exercise (3 days/week, ≥ 20 min/session)
Number of subjects: 19
Study 30659416 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined upper limb and breathing exercise
Number of subjects: 19
Study 30659416 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 19
Study 28398836 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative information module
Number of subjects: 213
Study 28398836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge module
Number of subjects: 213
Study 28398836 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative information module (high numeracy)
Number of subjects: 213
Study 25872506 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation at auricular acupoints (CO10, CO11, CO12, and TF4) innervated by the ABVN
Number of subjects: 120
Study 25872506 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation at auricular acupoints (CO10, CO11, CO12, and TF4) innervated by ABVN pairing tones
Number of subjects: 120
Study 25872506 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation at auricular acupoints innervated by non‐ABVN pairing tones
Number of subjects: 120
Study 25872506 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical acupuncture
Number of subjects: 120
Study 23540553 — intervention group
Group type: COMPARATOR
Intervention: IMRT
Number of subjects: 96
Study 21752985 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling kit
Number of subjects: 9709
Study 21752985 — intervention group
Group type: COMPARATOR
Intervention: Reminder letter
Number of subjects: 9709
Study 21752985 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of reminder letter and self-sampling
Number of subjects: 9709
Study 21752985 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-obtained samples
Number of subjects: 9709
Study 18384120 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema-focused therapy (SFT)
Number of subjects: 71
Study 18384120 — intervention group
Group type: COMPARATOR
Intervention: Transference-focused psychotherapy (TFP)
Number of subjects: 71
Study 21600104 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg/kg
Number of subjects: 80
Study 21600104 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 2 µg/kg
Number of subjects: 80
Study 16117882 — intervention group
Group type: COMPARATOR
Intervention: Artificial neural network model using serum protein fingerprinting
Number of subjects: 106
Study 12105352 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea syndrome
Number of subjects: 23
Study 12105352 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without obstructive sleep apnea syndrome)
Number of subjects: 23
Study 10734431 — intervention group
Group type: EXPERIMENTAL
Intervention: Deslorelin 700 micrograms
Number of subjects: 24
Study 10734431 — intervention group
Group type: EXPERIMENTAL
Intervention: Deslorelin 2100 micrograms
Number of subjects: 24
Study 10734431 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin
Number of subjects: 24
Study 10734431 — intervention group
Group type: COMPARATOR
Intervention: Control (saline, 2 mL, i.m.)
Number of subjects: 24
Study 7857353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod
Number of subjects: 748
Study 7857353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 748
Study 2683564 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfixation and/or repair of the triangular ligament after closed reduction of the fractured radius
Number of subjects: 41
Study 2683564 — intervention group
Group type: COMPARATOR
Intervention: Closed manipulation and above-the-elbow plaster cast
Number of subjects: 41
Study 989409 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation/chlorimipramine therapy
Number of subjects: 0
Study 989409 — intervention group
Group type: COMPARATOR
Intervention: Chlorimipramine therapy
Number of subjects: 0
Study 31118178 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Early Mobilisation (VEM)
Number of subjects: 2104
Study 31118178 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 2104
Study 28606206 — intervention group
Group type: EXPERIMENTAL
Intervention: Philani Intervention Program (home visiting intervention plus standard care)
Number of subjects: 1238
Study 28606206 — intervention group
Group type: COMPARATOR
Intervention: Standard Clinic Care (SC)
Number of subjects: 1238
Study 26562569 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.5%
Number of subjects: 64
Study 26562569 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09%
Number of subjects: 64
Study 26562569 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Number of subjects: 64
Study 26562569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24552647 — intervention group
Group type: COMPARATOR
Intervention: Total polyphenol intake (Q5 vs. Q1)
Number of subjects: 7172
Study 24552647 — intervention group
Group type: COMPARATOR
Intervention: Flavanols
Number of subjects: 7172
Study 24552647 — intervention group
Group type: COMPARATOR
Intervention: Lignans
Number of subjects: 7172
Study 24552647 — intervention group
Group type: COMPARATOR
Intervention: Hydroxybenzoic acids
Number of subjects: 7172
Study 22093663 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional progressive resistance exercise (PRE) training for 12 weeks, 3 times a week
Number of subjects: 51
Study 22093663 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 51
Study 22093663 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional progressive resistance exercise (PRE) training
Number of subjects: 51
Study 19474409 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐Fluorouracil (5‐FU)
Number of subjects: 250
Study 19474409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 16740505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun Protection is Fun! (SPF) intervention
Number of subjects: 245
Study 15308522 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination schedule at 0, 1, and 3 months
Number of subjects: 39
Study 15308522 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination schedule at 0, 1, and 6 months
Number of subjects: 39
Study 15308522 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 39
Study 11224758 — intervention group
Group type: COMPARATOR
Intervention: SonoVue (0.003 to 0.12 mL/kg for healthy volunteers; 4 mL for COPD patients)
Number of subjects: 78
Study 11224758 — intervention group
Group type: COMPARATOR
Intervention: SonoVue
Number of subjects: 78
Study 9767284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low incremental dose regimen
Number of subjects: 20
Study 9767284 — intervention group
Group type: COMPARATOR
Intervention: High incremental dose regimen
Number of subjects: 20
Study 9767284 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 20
Study 7977175 — intervention group
Group type: EXPERIMENTAL
Intervention: VAPE alternating with CCM
Number of subjects: 27
Study 7977175 — intervention group
Group type: COMPARATOR
Intervention: CCM alone
Number of subjects: 27
Study 7977175 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for CR patients
Number of subjects: 27
Study 7977175 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for PR patients
Number of subjects: 27
Study 7977175 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for NR patients
Number of subjects: 27
Study 2532583 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day sustained release preparation of anhydrous theophylline
Number of subjects: 10
Study 5428778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary scans showing high probability of pulmonary embolism (24 patients)
Number of subjects: 71
Study 5428778 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse, patchy, and non‐segmental perfusion defects (28 patients)
Number of subjects: 71
Study 5428778 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal lung scans (12 patients)
Number of subjects: 71
Study 30086103 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% polyhexamethylene biguanide (PHMB)
Number of subjects: 24
Study 30086103 — intervention group
Group type: COMPARATOR
Intervention: 0.8% metronidazole (control group)
Number of subjects: 24
Study 28274722 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation combined with 20-min tcDCS for 5 days
Number of subjects: 16
Study 28274722 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 26154250 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard training plus simulation‐based mastery training
Number of subjects: 52
Study 26154250 — intervention group
Group type: COMPARATOR
Intervention: Standard training
Number of subjects: 52
Study 24121307 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive, guided, self‐help, problem‐solving intervention through the Internet (n=49)
Number of subjects: 96
Study 24121307 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n=47)
Number of subjects: 96
Study 21903983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive angiotensin blockade
Number of subjects: 543
Study 19012954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef vaccine (n=1494)
Number of subjects: 3000
Study 19012954 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=1506)
Number of subjects: 3000
Study 19012954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef vaccine
Number of subjects: 3000
Study 19012954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study 16333821 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention (details not specified)
Number of subjects: 75
Study 11835021 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial 2 shocks programmed at 2 energy steps above DFT++ (typically 4‐6 J, maximum 10 J) with subsequent shocks at maximum energy
Number of subjects: 702
Study 11835021 — intervention group
Group type: COMPARATOR
Intervention: All shocks programmed at maximum energy
Number of subjects: 702
Study 11835021 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup randomization to energy levels of 0, 1, 2, 3, or 4 steps above implant DFT++ for conversion testing
Number of subjects: 702
Study 10522991 — intervention group
Group type: EXPERIMENTAL
Intervention: 17‐beta estradiol/norethisterone for 6 months
Number of subjects: 81
Study 10522991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 8547869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobe Spectra
Number of subjects: 10
Study 8547869 — intervention group
Group type: COMPARATOR
Intervention: Haemonetics MCS‐3P
Number of subjects: 10
Study 8547869 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both machines
Number of subjects: 10
Study 2328298 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg N-acetylcysteine (NAC)
Number of subjects: 10
Study 2328298 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg N-acetylcysteine (NAC)
Number of subjects: 10
Study 2328298 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg N-acetylcysteine (NAC) twice a day for 5 days
Number of subjects: 10
Study 2328298 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg N-acetylcysteine (NAC)
Number of subjects: 10
Study 7459147 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian Air Force exercise programme
Number of subjects: 0
Study 7459147 — intervention group
Group type: COMPARATOR
Intervention: Normal activities (Control)
Number of subjects: 0
Study 29547610 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil aromatherapy
Number of subjects: 70
Study 29547610 — intervention group
Group type: COMPARATOR
Intervention: Tea tree oil
Number of subjects: 70
Study 29547610 — intervention group
Group type: COMPARATOR
Intervention: Control group with no oil
Number of subjects: 70
Study 29027274 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural turmeric matrix formulation (CNTMF), 500 mg dose
Number of subjects: 45
Study 29027274 — intervention group
Group type: COMPARATOR
Intervention: Curcumin with volatile oil formulation, 500 mg dose
Number of subjects: 45
Study 29027274 — intervention group
Group type: COMPARATOR
Intervention: Curcumin with phospholipids formulation, 500 mg dose
Number of subjects: 45
Study 25632021 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled breathing (timed respiratory frequency with metronome, target tidal volumes displayed)
Number of subjects: 12
Study 25632021 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing
Number of subjects: 12
Study 25632021 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled breathing
Number of subjects: 12
Study 24008923 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (GL)
Number of subjects: 7
Study 24008923 — intervention group
Group type: EXPERIMENTAL
Intervention: White Rice (WR)
Number of subjects: 7
Study 24008923 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolled Barley (BAR)
Number of subjects: 7
Study 24008923 — intervention group
Group type: COMPARATOR
Intervention: Water (WAT)
Number of subjects: 7
Study 21087706 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized management with Hemostasis Management System Plus (HMS) following a modified protocol
Number of subjects: 90
Study 21087706 — intervention group
Group type: COMPARATOR
Intervention: Weight‐based anticoagulation management using activated clotting time (ACT)
Number of subjects: 90
Study 19005406 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 192
Study 19005406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 16997676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco screening
Number of subjects: 871
Study 16997676 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-related discussions
Number of subjects: 871
Study 16997676 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to quit smoking
Number of subjects: 871
Study 16997676 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of readiness to quit
Number of subjects: 871
Study 16997676 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral for smoking cessation
Number of subjects: 871
Study 16997676 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician empathy/encouragement
Number of subjects: 871
Study 14617313 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodified pooled random‐donor PLT concentrates
Number of subjects: 598
Study 14617313 — intervention group
Group type: COMPARATOR
Intervention: UV‐B‐irradiated PCs
Number of subjects: 598
Study 14617313 — intervention group
Group type: COMPARATOR
Intervention: Filtered PCs
Number of subjects: 598
Study 14617313 — intervention group
Group type: COMPARATOR
Intervention: Filtered random‐donor apheresis PLTs
Number of subjects: 598
Study 11094667 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of fentanyl 5 micrograms/ml in bupivacaine 0.2% with adrenaline 5 micrograms/ml at a rate of 2 ml/h for more than 48 hours
Number of subjects: 90
Study 11094667 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion of fentanyl 5 micrograms/ml in bupivacaine 0.2% without adrenaline at a rate of 2 ml/h for more than 48 hours
Number of subjects: 90
Study 9368200 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 30
Study 9368200 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 30
Study 9368200 — intervention group
Group type: EXPERIMENTAL
Intervention: NIMH LCM-p
Number of subjects: 30
Study 8218756 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ranitidine
Number of subjects: 15
Study 8218756 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ranitidine
Number of subjects: 15
Study 8218756 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg ranitidine
Number of subjects: 15
Study 8218756 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ranitidine
Number of subjects: 15
Study 8218756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3304515 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha 10 mg intravesically
Number of subjects: 36
Study 3304515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29873315 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based Heart Health Application
Number of subjects: 1000
Study 29873315 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1000
Study 27009868 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg/day)
Number of subjects: 1887
Study 27009868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1887
Study 23970480 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 12
Study 23652617 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 66
Study 23652617 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 66
Study 20110146 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (rosiglitazone and pioglitazone)
Number of subjects: 2860
Study 18180410 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (advised to reduce fat and to increase complex carbohydrate intake)
Number of subjects: 1013
Study 18180410 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (advised to reduce both fat and sugar and to increase complex carbohydrate intake)
Number of subjects: 1013
Study 18180410 — intervention group
Group type: COMPARATOR
Intervention: Control group (given no advice)
Number of subjects: 1013
Study 15699229 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1.5 g/d)
Number of subjects: 84
Study 15699229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 12553508 — intervention group
Group type: EXPERIMENTAL
Intervention: Two drains inserted (one below the fascia and one subcutaneously)
Number of subjects: 22
Study 12553508 — intervention group
Group type: COMPARATOR
Intervention: No drains
Number of subjects: 22
Study 9728902 — intervention group
Group type: EXPERIMENTAL
Intervention: Befloxatone (10 mg)
Number of subjects: 12
Study 9728902 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (50 mg)
Number of subjects: 12
Study 9728902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7857357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod (400 mg/day) for 60 days
Number of subjects: 101
Study 7857357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 7857357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod
Number of subjects: 101
Study 2658674 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (maintenance dose controlled to maintain light sleep levels C0 to D1)
Number of subjects: 20
Study 2658674 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (maintenance dose controlled to maintain deep sleep levels)
Number of subjects: 20
Study 1060201 — intervention group
Group type: EXPERIMENTAL
Intervention: Elmex fluid
Number of subjects: 0
Study 1060201 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 6102487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg twice daily
Number of subjects: 50
Study 6102487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 2 mg twice daily
Number of subjects: 50
Study 6102487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6102487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (both dosages)
Number of subjects: 50
Study 30828846 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg)
Number of subjects: 20
Study 30828846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28991599 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based education and coaching intervention (3-month group education + 3-month coaching)
Number of subjects: 102
Study 28991599 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 102